SarcoidosisNCT01745237
Prognostic Value of Clinical Cardiovascular MRI
An observational study of Sarcoidosis, run by Duke University at 1 site in United States.
Trial summary
The primary objective of this study is to identify findings on cardiovascular MR imaging (CMR) that are specific to various cardiac or vascular disorders in patients undergoing routine CMR scans. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sarcoidosis
- How many people
- 27,000 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2002to Jun 2032
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults referred for routine CMR scans
Who may be able to join
- Scheduled to undergo routine clinical CMR scan
Who cannot join
- Contraindication to MRI
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Duke University Medical Center
Durham, North Carolina, 27707
Han W Kim, MD, 919-668-3539, kim00050@duke.edu
Raymond J Kim, MD, 919-668-3539, kim00049@duke.edu
About this study
The primary objective of this study is to identify findings on cardiovascular MR imaging (CMR) that are specific to various cardiac or vascular disorders in patients undergoing routine CMR scans.
Read the detailed description
The objectives of this study are to 1) compare the information on your CMR scan to other clinical tests that you have undergone; and 2) determine whether the results of the CMR scan are predictive of future events related to heart or circulatory problems..
- Conditions
- Sarcoidosis
- Keywords
- Sarcoidosis, Cardiac Magnetic Resonance
- Medical subject headings
- Sarcoidosis
What is being measured
The primary outcome is the main question the study is designed to answer.
cardiac mortality
Measured: > 1year
arrhythmic death
Measured: > 1year
Pulmonary mortality
only in subset of patients with pulmonary sarcoidosis
Measured: > 1year
Secondary outcomes (5)
all-cause mortality
Measured: > 1year
arrhythmic events
Measured: > 1year
Pulmonary Transplant
Measured: > 1 year
Cardiac Transplant
Measured: > 1 year
PPM placement/high grade AV block
Measured: > 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2012 (estimated)
- Study startSep 2002
- Primary completionJun 2032 (estimated)
- Study completionJun 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SarcoidosisStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 27,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Raymond J Kim, MD, Principal investigator, Duke Cardiovascular Magnetic Resonance Center, Duke University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01745237
- Sponsor's protocol ID
- Pro00008224
- Other IDs
- DCMRC-8224a
- Status last verified
- Jul 2026
- First submitted
- 6 Dec 2012
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
Publications
Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009 Nov 17;120(20):1969-77. doi: 10.1161/CIRCULATIONAHA.109.851352. Epub 2009 Nov 2.
PubMed 19884472
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Value of Clinical Cardiovascular MRI
- ClinicalTrials.gov ID
- NCT01745237
- Acronym / sponsor ID
- Pro00008224
- Conditions
- Sarcoidosis
- Keywords
- Sarcoidosis, Cardiac Magnetic Resonance
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 27,000 participants (estimated)
- Lead sponsor
- Duke UniversityUniversity, hospital or other
- Study start
- Sep 2002 (actual)
- Primary completion
- Jun 2032 (estimated)
- Study completion
- Jun 2032 (estimated)
- First posted
- 10 Dec 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to identify findings on cardiovascular MR imaging (CMR) that are specific to various cardiac or vascular disorders in patients undergoing routine CMR scans.
Detailed description
The objectives of this study are to 1) compare the information on your CMR scan to other clinical tests that you have undergone; and 2) determine whether the results of the CMR scan are predictive of future events related to heart or circulatory problems..
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults referred for routine CMR scans
Key inclusion criteria (1 listed)
- Scheduled to undergo routine clinical CMR scan
Key exclusion criteria (1 listed)
- Contraindication to MRI
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
cardiac mortality
Time frame: > 1year
arrhythmic death
Time frame: > 1year
Pulmonary mortality
Time frame: > 1year
only in subset of patients with pulmonary sarcoidosis
5 secondary outcomes
all-cause mortality
Time frame: > 1year
arrhythmic events
Time frame: > 1year
Pulmonary Transplant
Time frame: > 1 year
Cardiac Transplant
Time frame: > 1 year
PPM placement/high grade AV block
Time frame: > 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Results publication: PubMed 19884472Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, Judd RM, Kim RJ. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009 Nov 17;120(20):1969-77. doi: 10.1161/CIRCULATIONAHA.109.851352. Epub 2009 Nov 2.
Related trials for Sarcoidosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingPhase 2
Repurposing Tilmanocept for Cardiac Sarcoidosis
Cardiac Sarcoidosis
RecruitingObservational study
Cardiac Sarcoidosis Multi-Center Prospective Cohort
Cardiac Sarcoidosis
RecruitingPhase 2/3
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
Cutaneous Sarcoidosis
Not yet recruitingPhase 2
An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Pulmonary Sarcoidosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Raymond J Kim, MD principal investigator
Duke Cardiovascular Magnetic Resonance Center, Duke University Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcoidosis, run by Duke University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Han W Kim, MD (919-668-3539, kim00050@duke.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
cardiac mortality (time frame: > 1year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01745237, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.